Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Laparoscopic pyeloplasty in adults--mid-term results in 32 laparoscopic pyeloplasties during 2003-2008].

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2009

Same author

[Mid-term outcomes and survival rates in patients with radical retropubic prostatectomy (RRP) under current Czech healthcare system].

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2009

Same author

[Outcomes of transperitoneal laparoscopic nephrectomy for renal adenocarcinoma].

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2009

Same author

Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?

Urologia internationalis·2008

Same author

Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.

Urology·2008

Same author

[Radical cystectomy in the treatment for bladder carcinoma: results of 125 operated patients].

Casopis lekaru ceskych·2007

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

[New aspects in prostate cancer therapy].

¹Urologická klinika 1. LF UK a VFN, Praha. jan.dvoracek@lf1.cuni.cz

Casopis Lekaru Ceskych

|November 21, 2007

Summary

Prostate cancer diagnosis has shifted, leading to earlier detection but also over-diagnosis. Advances in risk assessment and biomarkers aim to improve early detection and personalized treatment for prostate cancer patients.

Area of Science:

Oncology
Urology
Public Health

Context:

Prostate cancer is a leading cause of cancer death in men.
Recent shifts in clinical presentation necessitate new diagnostic and therapeutic strategies.
Long-term data highlight potential over-diagnosis and overtreatment issues, especially for low-risk prostate cancer.

Purpose:

To review the evolving landscape of prostate cancer diagnosis and treatment.
To discuss the implications of early-stage detection and risk stratification.
To explore advancements in risk assessment and biomarkers for personalized prostate cancer management.

Summary:

Prostate cancer diagnosis is increasingly occurring at earlier stages with lower risk features, largely due to PSA screening.
Despite earlier detection, there's a trend away from active surveillance towards increased rates of brachytherapy and hormonal therapy.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Jul 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Over-diagnosis remains a concern, where diagnosis may not improve lifespan or quality of life, necessitating careful treatment decisions.

Impact:

Improved risk assessment tools and novel biomarkers are crucial for accurate early diagnosis of prostate cancer.
Future advancements promise better patient selection for tailored treatment strategies, optimizing outcomes.
Understanding the balance between early detection and overtreatment is key to improving patient care and survival benefits in prostate cancer.